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OBJECTIVEdTo examine the cost-effectiveness of a hepatitis B vaccination program for un-
vaccinated adults with diagnosed diabetes in the U.S.
RESEARCHDESIGNANDMETHODSdWe used a cost-effectiveness simulationmodel
to estimate the cost-effectiveness of vaccinating adults 20–59 years of age with diagnosed di-
abetes not previously vaccinated for or infected by hepatitis B virus (HBV). The model estimated
acute and chronic HBV infections, complications, quality-adjusted life-years (QALYs), and in-
cremental cost-effectiveness ratios. Data sources included surveillance data, epidemiological
studies, and vaccine prices.
RESULTSdWith a 10% uptake rate, the intervention will vaccinate 528,047 people and pre-
vent 4,271 acute and 256 chronic hepatitis B infections. Net health care costs will increase by
$91.4 million, and 1,218 QALYs will be gained, producing a cost-effectiveness ratio of $75,094
per QALY gained. Results are most sensitive to age, the discount rate, the hepatitis B incidence
ratio for people with diabetes, and hepatitis B infection rates. Cost-effectiveness ratios rise with
age at vaccination; an alternative intervention that vaccinates adults with diabetes 60 years of age
or older had a cost-effectiveness ratio of $2.7 million per QALY.
CONCLUSIONSdHepatitis B vaccination for adults with diabetes 20–59 years of age is
modestly cost-effective. Vaccinating older adults with diabetes is not cost-effective. The study
did not consider hepatitis outbreak investigation costs, and limited information exists on hep-
atitis progression among older adults with diabetes. Partly based on these results, the Advisory
Committee on Immunization Practices recently recommended hepatitis B vaccination for people
20–59 years of age with diagnosed diabetes.
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The hepatitis B vaccine was ﬁrst rec-ommended in the U.S. in 1982 forgroups known to be at high risk of
hepatitis B virus (HBV) infection. Selective
vaccination of adults and infants at in-
creased risk for HBV infection was fol-
lowed by adoption of universal hepatitis B
vaccination for infants (1991) and catch-
up vaccination for adolescents up to 18
years of age (1995 and 1999) (1). This in-
cremental and selective vaccination strat-
egy for eliminating HBV transmission was
associated with an 84% decrease in
reported cases of acute hepatitis B from
1990 to 2009 (from 8.5 to 1.1 incident
cases per 100,000). When asymptomatic
infection, underdiagnosis, and underre-
porting are taken into account, the esti-
mated number of new HBV infections is
.10 times higher than the number of con-
ﬁrmed acute cases (2,3).
Despite these impressive improve-
ments, in recent years ;60% of acute
hepatitis B cases with risk factor informa-
tion had none of the previously recog-
nized risks for HBV infection (e.g.,
employment in a health care ﬁeld involv-
ing contact with human blood; dialysis;
injection drug use; multiple sexual part-
ners; men who have sex with men; or
household or sexual contact with a con-
ﬁrmed or suspected individual with an
HBV infection), suggesting that other
risks for HBV infection have not been
identiﬁed (2). From 1996 to 2011, 29
outbreaks of hepatitis B infection in
long-term care institutional facilities
were reported to the Centers for Disease
Control and Prevention (CDC). Twenty
ﬁve of the outbreaks involved adults
with diabetes receiving assisted blood
glucose monitoring (4). From 2008 to
2011, news media reported instances in
which.5,700 people were placed at risk
for bloodborne infection from misuse of
diabetes equipment (infection control
lapses related to assisted blood glucose
monitoring; use of diabetes equipment
[e.g., insulin pens and lancing devices]
designed for single-person use on multi-
ple people) (5). These events raised the
possibility that diabetes is a marker for
increased risk of HBV transmission
through exposure to contaminated blood
during diabetes care and monitoring.
The diabetes status of people with
acute hepatitis infection is not routinely
collected for national hepatitis surveillance
purposes. To examine the risk of acute
hepatitis B infection among adults with
diabetes, diabetes status was obtained for
865 conﬁrmed cases of acute hepatitis B
identiﬁed during 2009–2010 at eight
Emerging Infections Program sites (6). Af-
ter controlling for demographic character-
istics and stratifying by traditional risk
factors for HBV infection (injection drug
use, multiple sexual partners, and men
who have sex with men), adults with diag-
nosed diabetes 23–59 years of age who
lacked traditional risk factors for HBV in-
fection had twice the odds of acute hepatitis
B compared with adults without diabetes.
Moreover, adults with diagnosed diabetes
60 years of age or older who lacked tradi-
tional risk factors had a 50% higher odds of
acute hepatitis B compared with adults
without diabetes, although the difference
was not statistically signiﬁcant (6). These
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results were consistent with seropreva-
lence data from the 1999–2010 National
Health and Nutrition Examination Sur-
vey, which demonstrated a 60% increase
in the seroprevalence of current or past
HBV infection among adults with diag-
nosed diabetes compared with adults
without diagnosed diabetes, and a 30%
increase for adults with diagnosed diabe-
tes 60 years of age or older, which was
statistically signiﬁcant (CDC, unpub-
lished data). Together, these data support
the hypothesis that people with diag-
nosed diabetes are at increased risk of
HBV infection.
Options for preventing HBV infection
among adults with diagnosed diabetes
include increased emphasis on infection
control practice for diabetes care proce-
dures (4), modiﬁcations in the design of
diabetes care equipment to reduce the po-
tential for exposure to blood (7), and con-
sideration of pre-exposure hepatitis B
vaccination for adults with diabetes. In this
article, we examine the cost-effectiveness
of a hypothetical hepatitis B vaccination
program for unvaccinated adults with di-
agnosed diabetes.
RESEARCH DESIGN AND
METHODSdWe modiﬁed an existing
decision-analytic Markov model of vacci-
nation for hepatitis B and outcomes of
HBV infection (8,9) to reﬂect the impact
of hepatitis B in adults with diagnosed di-
abetes. The modiﬁcations accounted for
higher incidence of HBV infection among
adults with diagnosed diabetes, higher
mortality among people with diabetes,
and older age at peak diabetes prevalence.
Other model parameters were updated to
reﬂect current data.
The analysis begins with the choice of
vaccination strategy, which may include
vaccination or no vaccination. Outcomes
were assessed for the entire population of
U.S. adults 20–59 years of age who cur-
rently have diagnosed diabetes. The study
population was stratiﬁed into 5-year age-
groups. The model tracks hepatitis-re-
lated events from both acute and chronic
HBV infections.
Acute infection
More than half of patients who are acutely
infected with HBV are asymptomatic
(Supplementary Fig. 1A). For those who
develop symptoms, some recover without
hospitalization, whereas others are hospi-
talized. Some hospitalized patients de-
velop fulminant hepatic failure, which
can lead to death, liver transplant, or
recovery. Most patients who receive a
liver transplant survive, but some die.
Chronic infection
Acute infection is a necessary precursor to
chronic infection. Approximately 6% of
people who experience acute hepatitis B
develop chronic hepatitis B (Supplemen-
tary Fig. 1B). People with uncomplicated
chronic hepatitis can become inactive car-
riers, develop cirrhosis or hepatocellular
carcinoma (HCC), or remain with un-
complicated chronic hepatitis. Inactive
carriers can return to the chronic hepatitis
state, and they can transmit HBV to oth-
ers. People with cirrhosis can remain in
that state, develop compensated cirrhosis
or HCC, or die of hepatitis-related causes.
People with decompensated cirrhosis can
remain in that state, develop HCC,
receive a liver transplant, or die of hepa-
titis-related causes. People with HCC can
remain in that state, receive a liver trans-
plant, or die of hepatitis-related causes.
People in the liver transplant state can
survive or die of hepatitis-related causes.
At any time, people can die of other cau-
ses. Other-cause mortality rates are age
speciﬁc and represent all-cause mortality
for people with diabetes.
Incidence rates for susceptible
people with diagnosed diabetes
and other transition probabilities
The HBV infection rates for people with
diagnosed diabetes who are susceptible to
infection depend on the incidence of HBV
infection among all people with diag-
nosed diabetes, the prevalence of previ-
ous HBV infection, existing vaccine
coverage, and the efﬁcacy of prior vacci-
nation. The Supplementary Data de-
scribes components of the calculation.
Incidence rates for susceptible people
with diagnosed diabetes increase from
91 per 100,000 people with diabetes
20–24 years of age to a peak of 101 per
100,000 people 35–39 years of age, and
then decline to 13 per 100,000 people 70
years of age or older (Supplementary Ta-
ble 2). Other disease progression proba-
bilities and epidemiologic parameters are
listed in Table 1 (10–14).
Efﬁcacy of vaccination
Efﬁcacy of vaccination is based on a CDC
review (S.S., T.M., B. Baack, unpublished
data) (the Supplementary Data lists
source studies) of vaccine studies in
adults (19 studies) and people with diag-
nosed diabetes (10 studies). Efﬁcacy
declines with age, from 95% for 15–29
years of age to 40% for 70 years of age
or older (Supplementary Data).
Costs, health utilities, and
mortality rates
Table 1 contains all cost values and utility
values for health states. Direct program
costs and direct medical costs are in-
cluded. All ﬁnal cost ﬁgures were conver-
ted to 2010 U.S. dollars using the U.S.
Bureau of Labor Statistics’ Consumer Price
Index (All Urban Consumers, Medical
Care, U.S. City Average). The Supplemen-
tary Data describes the calculation of other-
cause mortality rates for people with
diabetes.
Intervention strategy
The primary vaccination strategy consid-
ered is vaccination with adult hepatitis B
vaccine (recombinant). Analyses of routine
vaccination of adults 20–59 years of age
with diabetes are based on assumptions
that vaccination will be offered to all adults
20–59 years of age with diagnosed diabe-
tes; 10% of adults with diagnosed diabetes
who are susceptible to hepatitis B and who
report no previous vaccination will ac-
cept the vaccination (the assumption is
based on hepatitis B vaccine uptake for
adults with previously recognized risk
factors, uptake for other adult vaccines,
and manufacturer projections) (Supple-
mentary Data); all people who accept
the vaccine will complete a primary series
of three doses (1 mL each) given on a 0-,
1-, and 6-month schedule or other ap-
proved schedule; immunity will not
wane over time for people achieving se-
roprotection; and vaccination will occur
during regularly scheduled patient visits
(76% of primary care ofﬁces stock hepa-
titis B vaccine for adults) (15).
The age-group 20–59 years was
chosen based on evidence of declining vac-
cination efﬁcacy in older age-groups and
preliminary analyses indicating that vac-
cination had very high cost-effectiveness
ratios among older age-groups. For com-
pleteness, the vaccination of adults 60 years
of age or older was analyzed as an alterna-
tive intervention strategy. The intervention
may be viewed as a catch-up strategy be-
cause vaccination will be offered to all peo-
ple who currently have diagnosed diabetes.
For purposes of the model, it is assumed
that people who refuse vaccination in the
ﬁrst year will not accept vaccination in sub-
sequent years; thus, all vaccination associ-
ated with the catch-up program will occur
during the ﬁrst year.
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Baseline strategy
The vaccination of adults with diagnosed
diabetes was compared with the status
quo of no additional vaccination. Under
the status quo strategy, some adults with
diabetes have previously been vaccinated
but no additional vaccination is assumed
to occur.
Analyses
For each vaccination strategy, incremental
cost-effectiveness ratios were calculated as
net costs per quality-adjusted life-year
Table 1dHepatitis B disease progression, cost, and health utilities parameters
Variable Base case Low High
Sensitivity analysis
distribution Reference
Acute hepatitis B transition probabilities
Rate of asymptomatic infections 0.70 0.60 0.80 Beta 10
Hospitalization rate 0.38 0.29 0.40 Beta 11
Fulminant cases 0.04 0.01 0.08 Beta 10
Liver transplants from fulminant cases 0.39 0.13 0.58 Beta 10
Death among fulminant cases 0.70 0.63 0.93 Beta 10
Successful transplantation 0.87 Beta 10
Acute→chronic hepatitis 0.06 0.03 0.10 Beta 10
Chronic hepatitis B transition probabilities
Chronic hepatitis 1→compensated cirrhosis 0.129 0.004 0.153 Beta 10
Chronic hepatitis 1→HCC 0.005 0.002 0.007 Beta 10
Chronic hepatitis 2→compensated cirrhosis 0.129 0.004 0.153 Beta 10
Chronic hepatitis 2→HCC 0.005 0.002 0.007 Beta 10
Compensated cirrhosis→decompensated cirrhosis 0.054 0.03 0.06 Beta 10
Compensated cirrhosis→HCC 0.024 0.002 0.081 Beta 10
Compensated cirrhosis→death 0.037 0.03 0.045 Beta 10
Decompensated cirrhosis→HCC 0.024 0.002 0.081 Beta 10
Decompensated cirrhosis→liver transplantation 1 0.018 0.015 0.024 Beta 10
Decompensated cirrhosis→death 0.39 0.3 0.5 Beta 10
HCC→liver transplantation 1 0.046 0.037 0.074 Beta 10
HCC→death 0.56 0.3 0.7 Beta 10
Chronic hepatitis 1→inactive carrier 0.17324 0.115 0.243 Beta 10
Chronic hepatitis 2→inactive carrier 0.105 0.060 0.163 Beta 10
Transplantation 1→death 0.15 0.096 0.217 Beta 10
Transplantation 2→death 0.015 0.002 0.041 Beta 10
Acute hepatitis B costs
Outpatient costs for symptomatic $402.24 $208.51 $700.02 Normal 10, 14
Hospitalization for nonfulminant $12,034.03 $2,561.77 $12,034.36 Normal 10, 14
Hospitalization for fulminant $19,481.32 $19,481.32 $52,322.63 Normal 10, 14
Chronic hepatitis B costs
Chronic hepatitis $1,824.47 $1,054.68 $8,729.28 Lognormal 10, 14
Inactive carrier $402.24 $89.37 $3,172.42 Lognormal 10, 14
Compensated cirrhosis $7,402.44 $417.04 $55,673.84 Lognormal 10, 14
Decompensated cirrhosis $46,864.32 $38,932.97 $153,110.51 Lognormal 10, 14
HCC $40,333.60 $12,510.98 $162,270.33 Lognormal 10, 14
Liver transplantation (ﬁrst year) $378,229.17 $343,241.59 $514,862.39 Lognormal 10, 14
Liver transplantation (subsequent year) $36,725.43 $33,112.38 $49,668.57 Lognormal 10, 14
Vaccination costs
Vaccine price (CDC) $28.00 $21.00 $35.00 Normal 13
Vaccine price (private) $52.50 $39.38 $65.63 Normal 13
Administration costs $14.42 $10.82 $18.02 Normal 14
Vaccine wastage 5% 5% 5% Not varied Assumption
Health utility levels
Diabetes 0.751 0.71 0.84 Beta 12
Inactive carrier 0.99 0.95 1.00 Beta 10
Chronic hepatitis 0.94 0.85 1.00 Beta 10
Compensated cirrhosis 0.82 0.46 1.00 Beta 10
Decompensated cirrhosis 0.54 0.19 1.00 Beta 10
HCC 0.49 0.15 0.95 Beta 10
Liver transplantation 0.86 0.66 1.00 Beta 10
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(QALY) gained. Net costs of vaccination
were estimated as vaccine costs and ad-
ministration costs minus averted medical
costs. The net costs were then divided by
the estimated improvement in QALYs re-
sulting from vaccination.
The perspective used is the health care
system perspective. The costs included the
direct costs to the health care system of
providing hepatitis B vaccination and the
direct medical costs of hepatitis B–related
illness and complications that are averted
by preventing HBV infection. The sum-
mary measure of effectiveness is QALYs
saved by the program. Productivity losses
associated with hepatitis-related morbidity
ormortality are not included in the analysis
because they are implicitly included in the
QALY measures (16).
QALYs saved by preventing acute and
chronic hepatitis B are estimated for the
remaining life expectancy of the target
population. The analytical horizon was
selected because available data suggest
that vaccine-induced immunity against
hepatitis B does not wane over time and
because chronic hepatitis B can lead to
serious health consequences years after an
acute infection. All future costs and beneﬁts
were discounted at a 3% annual rate.
Sensitivity analyses
In one-way sensitivity analyses, model
input parameters were individually varied
from their low to high values while
keeping all other variables ﬁxed. Param-
eter ranges are based on 95% CIs. When
95% CIs were not available, parameters
were varied between the highest and
lowest values identiﬁed in the litera-
ture or by 25% if only one value was
available.
In probabilistic sensitivity analyses,
parameters were varied simultaneously,
and the model was run 1,000 times. For
each run, key input parameterswere drawn
from appropriate distributions. Probability
and utility decrements were drawn from
beta distributions to ensure values between
0 and 1. Other disease parameters and
disease state costs were drawn from lognor-
mal distributions to account for skewness.
Costs for small, distinct medical events were
varied based on normal distributions. For
groupings of clearly associated variables
(vaccine efﬁcacy, hepatitis incidence, and
utility decrements), correlation between var-
iables was allowed when parameters were
drawn for individual runs. We estimated
95% credible intervals of the cost-effective-
ness ratio by bootstrapping the results of the
probabilistic sensitivity analysis (17).
The private cost of vaccine (which is
known) and the cost of administering the
vaccine were separately varied by a mul-
tiplicative factor between 0.75 and 1.25
for one-way sensitivity analyses and with a
corresponding normal distribution in prob-
abilistic sensitivity analyses. The discount
factor was varied from 0 to 5% in the one-
way sensitivity analysis and was not varied
in the probabilistic sensitivity analysis.
In addition to the one-way and prob-
abilistic sensitivity analyses, we considered
several alternative scenarios. Separately,
the age at vaccination was varied in 10-
year increments, the vaccine uptake rate
was varied from 5 to 40%, and the vaccine
was available at the CDC price.
RESULTS
Health outcomes
Projected reductions in acute and chronic
health outcomes resulting fromvaccination
are shown in Table 2. Vaccinating sus-
ceptible people with diagnosed diabetes
20–59 years of age with an assumed
10% uptake rate (main analysis) results
in vaccination of 528,047 people. This
program will prevent 4,271 acute HBV in-
fections over the course of the vaccinated
individuals’ lifetimes, 467 hospitalizations
for acute infections, 19 fulminant cases, 8
transplants, and 14 deaths from fulminant
hepatitis. The program will also prevent
256 cases of chronic HBV infection,
thereby preventing 146 cirrhosis cases, 56
decompensated cirrhosis cases, 33 HCC
cases, 5 transplants, and 116 deaths from
chronic hepatitis.
Vaccinating people with diagnosed di-
abetes 60 years of age or older and people
with diagnosed diabetes 20 years of age or
older (the alternative strategies analyzed)
would prevent 723 and 4,994 acute HBV
infections, respectively. Although a large
number of people 60 years of age or older
would be vaccinated, few acute and chronic
cases would be prevented.
Cost-effectiveness
The vaccination program increases net
costs and increases QALYs (Table 3). The
point estimate of the incremental cost-
effectiveness ratio of hepatitis B vaccina-
tion for people 20–59 years of age with
diagnosed diabetes is $75,094 per QALY.
The cost-effectiveness ratio for the alterna-
tive strategy of vaccinating adults with di-
agnosed diabetes 20 years of age or older is
$196,557 per QALY; vaccinating only
adults with diagnosed diabetes 60 years
of age or older produces a cost-effectiveness
ratio of $2,760,753 per QALY.
The cost-effectiveness ratios increase
with age at vaccination. The factors un-
derlying this increase are discussed below.
Table 2dAcute and chronic health outcomes prevented by hepatitis B vaccination
Number
vaccinated with
10% uptake rate
Acute cases prevented
Age-groups
vaccinated Infected
Acute
symptomatic Hospitalizations
Fulminant
cases Transplants
Fulminant
deaths
20–59 528,047 4,271 1,281 467 19 8 14
60+ 774,394 723 217 79 3 1 2
All ages, 20+ 1,302,441 4,994 1,498 547 23 9 16
Chronic cases prevented
Age-groups
vaccinated
Chronic
cases Cirrhosis
Decompensated
cirrhosis HCC Transplants
Chronic
deaths
20–59 256 146 56 33 5 116
60+ 43 17 5 3 0 9
All ages, 20+ 300 164 60 36 5 125
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Sensitivity analyses
Figure 1 shows a tornadodiagramdepicting
the cost-effectiveness results of the one-way
sensitivity analyses. The center line of the
tornado is the baseline cost-effectiveness ra-
tio of $75,094 per QALY gained. For pre-
sentation purposes for certain related
groups of parameters (complication costs,
chronic hepatitis transition probabilities,
acute infection transition probabilities,
and complication utilities), we set all pa-
rameters in the group to their low and
high values. The effects of varying individ-
ual parameters within these groups were
smaller than the aggregated effects for the
group. The parameter labels in Fig. 1 in-
dicate which values were associated with
improved cost-effectiveness and which
resulted in worse cost-effectiveness. Re-
sults were most sensitive to the discount
rate, with no discounting improving cost-
effectiveness to $27,000 per QALY, and
a 5% discount rate resulting in $128,000
per QALY. Results were also sensitive to
the hepatitis B incidence ratio for people
with diagnosed diabetes relative to peo-
ple without diabetes, hepatitis B progres-
sion rates, and complication costs.
The cost-effectiveness ratio based on
the probabilistic sensitivity analysis re-
sults is $74,478 per QALY gained, slightly
lower than the results using baseline
values. The bootstrapped 95% credible
interval for the cost-effectiveness ratio
ranges from $69,000 to $80,400 per
QALY gained.
Alternative uptake rates
As uptake rates increase, net costs and
QALYs saved increase as more people are
vaccinated. The cost-effectiveness ratio
does not change because its numerator
and denominator increase proportion-
ately (Supplementary Data).
CDC vaccine prices
If the hepatitis B vaccine were available at
the lower CDC price, the program cost
would decline and the cost-effectiveness
ratio would decrease to $41,622 per
QALY gained (Supplementary Data).
CONCLUSIONSdNo previous study
has analyzed the cost-effectiveness of
hepatitis B vaccination among adults
with diabetes. Hepatitis B vaccination
for adults with diagnosed diabetes ,60
years of age costs ;$75,000 per QALY
saved, a value substantiated over a prob-
abilistic range of input parameters. For all
adults with diagnosed diabetes 20 years
of age or older, hepatitis B vaccination is
less cost-effective at a cost per QALY
saved of ;$197,000.
Three factors contribute to the vary-
ing cost-effectiveness of hepatitis B vacci-
nation for people with diagnosed diabetes
by age-group at vaccination: hepatitis B
incidence decreases after 40 years of age
(2), vaccine immunogenicity declines
with age (Supplementary Data), and
older people spend fewer years at risk
for hepatitis complications because
their remaining life expectancy is
shorter. These considerations suggest
both clinical and economic rationales
for vaccination soon after diabetes diag-
nosis.
The cost-effectiveness of hepatitis B
vaccination for adults with diagnosed diabe-
tes is within the range of cost-effectiveness
of selected diabetes management interven-
tions and adult immunizations. Li et al.
(18) reviewed the cost-effectiveness of 44
interventions for diabetes and classiﬁed
most as cost-saving, very cost-effective
(cost-effectiveness ratio between $0 and
$25,000 per QALY), or cost-effective
(cost-effectiveness ratio between $25,001
and $50,000 per QALY). Hepatitis B vacci-
nation would be classiﬁed as marginally
cost-effective (cost-effectiveness ratio be-
tween $50,001 and $100,000 per QALY)
under the Li et al. (18) approach, along
with four of the interventions reviewed
by Li et al. Cost-effectiveness ratios for
adult zoster and pneumococcal vaccina-
tion range from $16,229 to .$100,000
(19,20) and from cost saving to $66,818
(21) per QALY saved, respectively.
Assuming a 10% vaccine uptake
rate, a hepatitis B vaccination program
for adults with diagnosed diabetes 20–59
years of age would cost ;$110 million in
its ﬁrst year. If uptake rates increase, pro-
gram costs will increase but the cost per
QALYs saved will remain unchanged be-
cause net costs and QALYs saved increase
proportionately. Unlike other adult vacci-
nation programs, costs would be expected
to decline over time as the vaccinated pe-
diatric cohort ages into adulthood.
This analysis has several limitations.
The private vaccine price ($52.50) was
used as an input parameter because the
proportion of people who would receive
vaccine at the CDC vaccine price ($28.00,
the price for vaccine obtained through
CDC contracts for immunization pro-
grams that receive CDC immunization
grant funds; private providers and private
citizens cannot directly purchase vaccines
through CDC contracts) could not be
estimated. Some studies used to derive
ﬁgures for vaccine efﬁcacy had small
sample sizes or included people with
diabetes in a secondary analysis. We did
not include adverse events associated
with vaccination. However, the hepatitis
B vaccine is considered very safe. Public
health costs for outbreak investigations
and beneﬁts from herd immunity were
not included in the model. The model
Table 3dEstimated outcomes and impact of age at hepatitis B vaccination on results
Age
Number vaccinated
with 10% uptake Program cost Medical costs saved Net costs QALYs saved Cost per QALY saved
20–59 528,047 $110,172,395 $18,745,140 $91,427,255 1,218 $75,094
60+ 774,394 $161,570,643 $2,352,214 $159,218,429 58 $2,760,753
All ages, 20+ 1,302,441 $271,743,038 $21,097,354 $250,645,684 1,275 $196,557
20–29 33,244 $6,936,177 $3,697,321 $3,238,856 307 $10,563
30–39 46,486 $9,698,834 $3,558,661 $6,140,173 260 $23,649
40–49 218,591 $45,607,150 $8,275,520 $37,331,630 501 $74,469
50–59 229,725 $47,930,235 $3,213,638 $44,716,597 150 $298,204
60–69 383,679 $80,051,421 $1,629,596 $78,421,825 47 $1,674,634
70–79 239,182 $49,903,263 $540,218 $49,363,045 9 $5,252,858
80–89 126,196 $26,329,759 $161,670 $26,168,089 1 $19,165,424
90–99 25,336 $5,286,200 $20,730 $5,265,469 0 $65,729,814
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assumed that vaccination would be pro-
vided during regularly scheduled health
care visits (which could underestimate
costs) and that all people vaccinated
would receive the complete series. People
with diagnosed diabetes,60 years of age
were estimated to be twice as likely to be
infected with HBV compared with people
without diabetes (22), and hepatitis B–
associated morbidity is potentially high.
Although not reﬂected in our calculations,
people with diabetes who develop HBV
infection might be more likely than other-
wise healthy adults to develop serious se-
quelae of infection; acute HBV infection
leads to the development of chronic infec-
tion (which can lead to cirrhosis, liver fail-
ure, and liver cancer) in;5% of otherwise
healthy adults (23), but development of
chronic infection might be more frequent
among older adults (24). Mortality after
acute infection is also increased; hepatitis
B–associated deaths among people with
diabetes in recent outbreaks in long-term
care facilities reached as high as 75% (25),
whereas 1–3% of otherwise healthy adults
in nonoutbreak settings (CDC, unpub-
lished data) die as a result of their acute
infection. In addition, a recent popula-
tion-based study found that people with
both diabetes (deﬁned as fasting glucose
$126 mg/dL or history of oral hypoglyce-
mic or insulin use, or both) and chronic
HBV infection had ;30 times the risk of
death as people without diabetes with
chronic infection (26).
Given the higher incidence of hepati-
tis B among people with diagnosed di-
abetes and the cost-effectiveness ratio of
$75,094 per QALY gained of hepatitis B
vaccination for people with diagnosed
diabetes 20–59 years of age, on 25
October 2011, the Advisory Committee on
Immunization Practices recommended
hepatitis B vaccination for these individu-
als as a primary preventive measure. For
older adults with diagnosed diabetes, the
frequency of current or anticipated future
need for assisted monitoring of blood glu-
cose and other diabetes procedures should
be incorporated into the clinical decision-
making process for recommending hepatitis
B vaccination, particularly early in the
course of diabetes.
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Figure 1dOne-way sensitivity analyses of cost-effectiveness of hepatitis B vaccination for people with diagnosed diabetes, 20–59 years of age.
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